Business
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)The Final Results from the Trial are Anticipated in 2026 CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the tre
About this update from Actuate Therapeutics, Inc.
[{"type":"image","alt":"Actuate Therapeutics","displaySize":"","headline":null,"caption":"Actuate Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/8600bbc6448d867dc281bd537c05e09e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/33fX_k368HBbxSS0OT6lrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8600bbc6448d867dc281bd537c05e09e","width":300,"height":117}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"The Final Results from the Trial are Anticipated in 2026","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":275,"olType":false},{"type":"text","content":"CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced the completion of patient enrollment in the ongoing Phase 2 trial of FOLFIRINOX in combination with elraglusib and losartan for untreated metastatic pancreatic adenocarcinoma (mPDAC). The trial is being led by Colin Weekes MD PhD at Massachusetts General Hospital and is supported by the Lustgarten Foundation as well as Actuate Therapeutics. Additional sites participating in the study include The University of Colorado (led by Cristopher Lieu, MD) and the University of Washington’s Fred Hutchinson Cancer Center (led by Andrew Coveler, MD).","length":896,"tagName":"p"},{"type":"text","content":"The trial enrolled 56 treatment-naïve mPDAC patients. The primary objectives of this Phase 2 open-label, non-comparator study (NCT05077800) are to determine the safety, tolerability, and progression-free survival of the combination of elraglusib with FOLFIRINOX and losartan .","length":276,"tagName":"p"},{"type":"text","content":"“The completion of enrollment in this trial represents an i...